Literature DB >> 27400681

GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.

Jiangning Gu1, Di Wang2, Jiaqiang Zhang3, Yi Zhu4, Ying Li5, Hao Chen3, Minmin Shi6, Xuelong Wang5, Baiyong Shen3, Xiaxing Deng3, Qian Zhan3, Gang Wei7, Chenghong Peng8.   

Abstract

Nerve growth factors and their receptors have received an increasing attention in certain cancers since they play an important role in regulating tumorigenesis, biological process and metastasis. Here we aimed at characterizing a new function of one of the subtypes of growth factor receptors (GFR), GFRα2, in pancreatic cancer. In this study, we showed that GFRα2 was up-regulated in pancreatic adenocarcinoma and was positively correlated with tumor size and perineural invasion, which indicated that it may be associated with cell growth and apoptosis. Mechanically, we discovered that high GFRα2 expression level leads to PTEN inactivation via enhancing Mir-17-5p level.
Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Chemoresistance; GFRα2; Mir-17-5p; PTEN; Pancreatic cancer

Mesh:

Substances:

Year:  2016        PMID: 27400681     DOI: 10.1016/j.canlet.2016.06.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

1.  Schisandrin B Attenuates Inflammation in LPS-Induced Sepsis Through miR-17-5p Downregulating TLR4.

Authors:  Zhi-Rong Ji; Wei-Liang Xue; Ling Zhang
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

2.  The Impact of Serum Glucose in the Treatment of Locoregionally Advanced Pancreatic Cancer.

Authors:  Nick A Iarrobino; Beant S Gill; Rainer J Klement; Mark E Bernard; Colin E Champ
Journal:  Am J Clin Oncol       Date:  2019-09       Impact factor: 2.339

Review 3.  The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.

Authors:  Qinyi Wang; Junmin Wang; Hongjiao Xiang; Peilun Ding; Tao Wu; Guang Ji
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 4.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

5.  Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.

Authors:  Lifen Zhao; Yujia Shan; Bing Liu; Yang Li; Li Jia
Journal:  Cell Death Dis       Date:  2017-05-25       Impact factor: 8.469

6.  Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.

Authors:  Guanhua Zhang; Ye-Hua Gan
Journal:  Oncol Rep       Date:  2017-09-21       Impact factor: 3.906

7.  CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.

Authors:  Sujie Ni; Hongwei Wang; Xiaolin Zhu; Chunhua Wan; Junfei Xu; Chen Lu; Li Xiao; Jiaqi He; Chongyi Jiang; Wei Wang; Zhixian He
Journal:  Oncotarget       Date:  2017-01-31

Review 8.  MicroRNAs: emerging driver of cancer perineural invasion.

Authors:  Mei Zhang; Hong-Chun Xian; Li Dai; Ya-Ling Tang; Xin-Hua Liang
Journal:  Cell Biosci       Date:  2021-06-29       Impact factor: 7.133

9.  Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.

Authors:  Chengdi Yang; Wenbo Yuan; Xiao Yang; Peng Li; Jingzi Wang; Jie Han; Jun Tao; Pengchao Li; Haiwei Yang; Qiang Lv; Wei Zhang
Journal:  Mol Cancer       Date:  2018-01-31       Impact factor: 27.401

10.  Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway.

Authors:  Jie Pan; Jiaying Shen; Wengong Si; Chengyong Du; Danni Chen; Liang Xu; Minya Yao; Peifen Fu; Weimin Fan
Journal:  Oncotarget       Date:  2017-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.